| 摘要 |
The present disclosure relates to synthetic alpha-galactosyl ceramide (.a lpha.-GalCer) analogs, and their use as immunotherapies. In one aspect, a me thod of activating a cytokine response in a subject includes administering a n effective amount of a compound to a subject, wherein the subject has an ad aptive immune system that includes a population of cells, the population inc luding at least one lymphocyte and at least one antigen-presenting cell, and wherein the compound is represented by the structure of formula (1) wherein , n is 0 to 25; X is selected from O and S; R1is selected from H, CH3, and p henyl, where phenyl is optionally substituted with H, OH, OCH3, F, CF3, phen yl, phenyl-F, C1-C6 alkyl, or C2-C6 branched alkyl; R2 is selected from OH a nd H; R3 is selected from C1-C15 alkyl, and phenyl, where phenyl is optional ly substituted with H, OH, OCH3, F, CF3, phenyl, C1-C6 alkyl, or C2-C6 branc hed alkyl; R4 is selected from OH, OSO3H, OSO3Na, and OSO3K; and R5 is selec ted from CH2OH and CO2H; or a pharmaceutically acceptable salt thereof; form ing a complex between the compound and the antigen-presenting cell, wherein the formation of the complex results in the activation of a receptor on the lymphocyte; and activating the lymphocyte to produce the cytokine response.
|
